GLP-1 & Incretin Science

Why Population-Specific Trials Are Run

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

OASIS 2 was a randomised clinical trial of oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes, published by Kadowaki and colleagues in JAMA Internal Medicine in October 2025.

Key facts

Trial
OASIS 2
Compound
Oral semaglutide
Population
East Asian, overweight or obesity
With or without
Type 2 diabetes
Published
JAMA Intern Med, 1 October 2025
PMID
40758358

Why population-specific trials exist

Not as a formality. Body composition at a given body mass index differs between populations, and the BMI thresholds defining overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI. A trial recruiting to different thresholds is studying a different population, not the same one relabelled.

What differs pharmacologically

Body weight itself, which affects volume of distribution and therefore exposure at a fixed dose. Baseline body composition. Background diet and the prevalence of comorbidities. Genetic variation in drug-metabolising enzymes for compounds that depend on them. Each can shift the dose-response relationship without anything about the drug changing.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why an oral formulation raises the stakes

Oral semaglutide depends on the absorption enhancer SNAC and on strict administration conditions. A fasting window and a defined volume of water. Anything affecting gastric conditions affects absorption, and absorption of this formulation is variable to begin with. A route that fragile is more sensitive to population differences than a subcutaneous injection.

What including and excluding diabetes achieves

Recruiting participants with and without type 2 diabetes allows the same trial to describe both, and weight response has consistently been smaller in people with diabetes across this drug class. Reporting them together without separating them would produce an average describing neither group.

Why this matters for reading any headline figure

A weight-reduction percentage is a property of a trial, not of a molecule. Population, baseline weight, duration, diabetes status and estimand all move it. Two honest trials of the same drug can report meaningfully different numbers, and neither is wrong.

What it does not concern

Research material. OASIS 2 studied a licensed medicine in a defined population under clinical supervision. Nothing supplied here is semaglutide, in any formulation, or an alternative to it.

Frequently asked questions

Why run a separate trial in an East Asian population?

BMI thresholds for overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI, so the population differs.

Why does the oral formulation make this more important?

It depends on the SNAC absorption enhancer and strict administration conditions, so it is more sensitive to anything affecting gastric conditions.

Does diabetes status change the weight result?

Yes. Weight response has consistently been smaller in people with type 2 diabetes across this drug class.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.